COVID-19, caused by SARS-CoV-2, has emerged as the most destructive emerging infectious disease of the 21st century. Vaccination is an effective method to combat viral diseases. However, due to the constant mutation of the virus, new variants may weaken the efficacy of vaccines. In the current field of new coronavirus research, viral protease inhibitors have emerged as a highly regarded therapeutic strategy. Nevertheless, existing viral protease inhibitors do not fully meet the therapeutic needs. Therefore, this paper turned to traditional Chinese medicine to explore new active compounds. This study focused on 24 isolated compounds from Acorus calamus L. and identified 8 active components that exhibited significant inhibitory effects on SARS-CoV-2 PLpro. Among these, the compound 1R,5R,7S-guaiane-4R,10R-diol-6-one demonstrated the best inhibitory activity with IC50 values of 0.386 ± 0.118 μM. Additionally, menecubebane B and neo-acorane A exhibited inhibitory activity against both Mpro and PLpro proteases, indicating their potential as dual-target inhibitors. The molecular docking results confirmed the stable conformations of these compounds with the key targets and their good activity. ADMET and Lipinski’s rule analyses revealed that all the small molecule ligands possessed excellent oral absorption properties. This study provides an experimental foundation for the discovery of promising antiviral lead compounds.
This review reveals that Morinda citrifolia L., with bioactive components, alleviates systemic metabolic disorders through multiple mechanisms, provides in vitro / in vivo evidence, and highlights its potential as a natural intervention for SMD.
Osteoporosis is a heterogeneous skeletal disorder arising from diverse age-related, endocrine, metabolic, mechanical, and pharmacological factors. In age-related, postmenopausal, and selected metabolism-associated forms of osteoporosis, immunosenescence may contribute to dysfunction in the bone marrow immune niche, thereby amplifying bone resorption and regenerative decline. This review examines osteoporosis through the complementary perspective of the bone marrow immune niche and summarizes the core mechanisms by which immunosenescence contributes to destabilization of the bone marrow immune niche in osteoporosis. On this basis, we further discuss the molecular basis and regulatory potential of natural products in mediating bone marrow-related immune microenvironmental reprogramming. Emerging technologies, including single-cell omics, spatial omics, organoid models, and humanized research platforms, are also integrated to propose novel strategies for the precision prevention and treatment of osteoporosis. Overall, this review incorporates immune microenvironmental regulation into the conventional framework of bone metabolic dysfunction and provides a systematic theoretical basis for mechanistic elucidation, precision delivery, and clinical translation of natural products in prevention and treatment of osteoporosis.
Vascular dementia (VaD) is a heterogeneous cognitive disorder associated with cerebrovascular pathology and persistent vascular dysfunction. Because effective disease-modifying therapies remain limited, natural products have attracted interest as potential interventions for the complex pathology of VaD. This review examines their effects from two complementary perspectives: neuroprotection and neural repair. Experimental studies indicate that natural products can influence several interconnected processes, including redox imbalance, neuroinflammation, cell survival, blood–brain barrier dysfunction, vascular remodeling, neurogenesis, and synaptic plasticity. However, the available evidence varies considerably among isolated compounds, botanical extracts, and herbal formulations. Some isolated compounds have been supported by relatively coherent relationships between molecular targets, tissue responses, and functional outcomes, whereas evidence from clinical studies remains much more limited. We therefore consider the current mechanistic evidence together with the major challenges in pharmacokinetics, quality control, and clinical translation.